Evidence mapPaperPMID 41756253Full record

ReviewMedComm2026

RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.

Xuan Yin, Zengkan Du, Shuya Jiang, Yan Liao, Changli Wang, Jiaqi Li, Haoling Zhang, Ting-Ting Wei, Wangzheqi Zhang, Zui Zou

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuan YinFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.
Zengkan DuDepartment of Gastroenterology, National Clinical Research Center For Digestive Diseases, Changhai Hospital Naval Medical University Shanghai China.
Shuya JiangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital Naval Medical University Shanghai China.
Yan LiaoFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.
Changli WangFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.
Jiaqi LiFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.
Haoling ZhangDepartment of Biomedical Science Universiti Sains Malaysia Penang Malaysia.
Ting-Ting WeiDepartment of Laboratory Medicine, Shanghai Changzheng Hospital Naval Medical University Shanghai China.
Wangzheqi ZhangFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.
Zui ZouFaculty of Anesthesiology, Changhai Hospital Naval Medical University Shanghai China.ORCID https://orcid.org/0000-0002-8433-8388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a global health challenge. The initiation and progression of cancer are correlated with dynamic dysregulation of RNA regulatory networks. This review systematically explains how contending RNAs (including mRNA, miRNA, lncRNA, circRNA, etc.) remold gene expression programs across multiple dimensions. They do this primarily through the competing endogenous RNA sponge effect, RNA-protein complex assembly, RNA editing (A-to-I editing, m6A modification, etc.), tumorigenesis, heterogeneous evolution, and therapeutic resistance. RNA regulatory networks do not only help one to decode cancer biology but because they are dynamic in nature, they are now also being looked at as good precision targets for diagnosis and treatment. This article integrates recent findings on the emerging functions of RNA networks in tumor metabolic reprogramming, tumor immune microenvironment shaping, and cancer stem cell property maintenance, while highlighting their clinical application prospects as liquid biopsy biomarkers. Our therapies focus on assessing the potential and clinical translation bottlenecks of novel RNA-targeted interventions, including antisense oligonucleotides, RNA aptamers, and the CRISPR-Cas13 system. A dynamic adjustability made the RNA-targeted therapies promising intervention nodes in precision medicine even if most of them are still in a preclinical state.

Indexed as

cancerliquid biopsyprecision medicineRNA regulatory networktherapeutic target

Identifiers

PMID41756253
PMCPMC12932978

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.